TY - JOUR
T1 - Guidelines of the International Headache Society for controlled trials of preventive treatment of migraine attacks in episodic migraine in adults
AU - on behalf of the International Headache Society Clinical Trials Committee
AU - Diener, Hans Christoph
AU - Tassorelli, Cristina
AU - Dodick, David W.
AU - Silberstein, Stephan D.
AU - Lipton, Richard B.
AU - Ashina, Messoud
AU - Becker, Werner J.
AU - Ferrari, Michel D.
AU - Goadsby, Peter J.
AU - Pozo-Rosich, Patricia
AU - Wang, Shuu Jiun
AU - Houle, Timothy T.
AU - Hoek, Thomas C.van den
AU - Martinelli, Daniele
AU - Terwindt, Gisela M.
N1 - Publisher Copyright:
© International Headache Society 2020.
PY - 2020/9/1
Y1 - 2020/9/1
N2 - Clinical trials are a key component of the evidence base for the treatment of headache disorders. In 1991, the International Headache Society Clinical Trials Standing Committee developed and published the first edition of the Guidelines for Controlled Trials of Drugs in Migraine. Advances in drugs, devices, and biologicals, as well as novel trial designs, have prompted several updates over the nearly 30 years since, including most recently the Guidelines for controlled trials of preventive treatment of chronic migraine (2018), the Guidelines for controlled trials of acute treatment of migraine attacks in adults (2019), and Guidelines for controlled trials of preventive treatment of migraine in children and adolescents (2019). The present update incorporates findings from new research and is intended to optimize the design of controlled trials of preventive pharmacological treatment of episodic migraine in adults. A guideline for clinical trials with devices will be published separately.
AB - Clinical trials are a key component of the evidence base for the treatment of headache disorders. In 1991, the International Headache Society Clinical Trials Standing Committee developed and published the first edition of the Guidelines for Controlled Trials of Drugs in Migraine. Advances in drugs, devices, and biologicals, as well as novel trial designs, have prompted several updates over the nearly 30 years since, including most recently the Guidelines for controlled trials of preventive treatment of chronic migraine (2018), the Guidelines for controlled trials of acute treatment of migraine attacks in adults (2019), and Guidelines for controlled trials of preventive treatment of migraine in children and adolescents (2019). The present update incorporates findings from new research and is intended to optimize the design of controlled trials of preventive pharmacological treatment of episodic migraine in adults. A guideline for clinical trials with devices will be published separately.
UR - http://www.scopus.com/inward/record.url?scp=85088843506&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85088843506&partnerID=8YFLogxK
U2 - 10.1177/0333102420941839
DO - 10.1177/0333102420941839
M3 - Article
C2 - 32722936
AN - SCOPUS:85088843506
SN - 0333-1024
VL - 40
SP - 1026
EP - 1044
JO - Cephalalgia
JF - Cephalalgia
IS - 10
ER -